Gene Therapy: A Promising Approach for Neuroprotection in Parkinson’s Disease? by Pamela Valdés & Bernard L. Schneider
MINI REVIEW
published: 20 December 2016
doi: 10.3389/fnana.2016.00123
Gene Therapy: A Promising Approach
for Neuroprotection in Parkinson’s
Disease?
Pamela Valdés and Bernard L. Schneider *
Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
Edited by:
Jose L. Lanciego,
Universidad de Navarra, Spain
Reviewed by:
José A. Armengol,
Pablo de Olavide University, Spain
Kazuto Kobayashi,
Fukushima Medical University, Japan
*Correspondence:
Bernard L. Schneider
bernard.schneider@epfl.ch
Received: 30 August 2016
Accepted: 06 December 2016
Published: 20 December 2016
Citation:
Valdés P and Schneider BL
(2016) Gene Therapy: A Promising
Approach for Neuroprotection in
Parkinson’s Disease?
Front. Neuroanat. 10:123.
doi: 10.3389/fnana.2016.00123
With the development of effective systems for gene delivery to the central nervous
system (CNS), gene therapy has become a therapeutic option for the treatment of
Parkinson’s disease (PD). Gene therapies that are the most advanced in the clinic
have been designed to more effectively compensate for the lack of dopamine signaling
in the basal ganglia and rescue the cardinal motor symptoms of PD. However,
it remains essential to devise novel therapies to prevent neurodegeneration and
disease progression. Since gene therapy has been initially proposed for the delivery
of neurotrophins to support the survival and function of dopaminergic neurons, our
understanding of PD etiology has changed dramatically. Genes implicated in familial
forms of the disease and genetic risk factors associated with sporadic PD have been
identified. The spreading of the α-synuclein pathology, as well as perturbations of the
lysosomal and mitochondrial activities, appear to play critical roles in the pathogenesis.
These findings provide novel targets for gene therapy against PD, but at the same
time underline the complexity of this chronic disease. Here we review and discuss the
successes and limitations of gene therapy approaches, which have been proposed to
provide neuroprotection in PD.
Keywords: Parkinson’s disease, gene therapy, neuroprotection, risk factors, mitochondria, autophagy,
neurotrophic factors
INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative disease whichmainly affects the central
nervous system (CNS) and in particular the basal ganglia. Themost salient histopathological feature
of PD is the widespread deposition of the misfolded α-synuclein protein in the brain, and already at
early stages of the disease, in neurons innervating peripheral organs, such as the gut and the heart
(Klingelhoefer and Reichmann, 2015). The most studied and best understood degenerative process
caused by PD is the loss of dopaminergic neurons localized in the substantia nigra pars compacta,
and projecting to the striatum. Indeed, nigral neuron loss leads to deficits in the initiation and
control of voluntary movements, which represent the cardinal symptoms of PD.
Gene therapy has been considered as a promising therapeutic approach for PD. This notion has
been spurred by the possibility to genetically modify neuronal populations of the basal ganglia,
to compensate for the lack of dopamine release and rescue the activity of the circuit controlling
movement initiation. Indeed, gene delivery systems, mainly based on the viral vector technologies,
have demonstrated their efficacy for gene transfer to nuclei critically involved in the disease, such
as the substantia nigra, the subthalamic nucleus or the striatum. The most advanced therapeutic
approaches based on gene delivery aim at alleviating themotor symptoms or prevent the occurrence
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of dyskinesia, by improving the efficacy of dopamine
replacement (Coune et al., 2012). Notably, Prosavin has
recently reached a phase I/II clinical trial, demonstrating
efficacy in restoring dopamine levels in the striatum, which may
represent an appealing alternative to levodopa administration
(Palfi et al., 2014). This therapy is based on an equine lentiviral
vector encoding tyrosine hydroxylase, GTP cyclohydrolase
and aromatic acid decarboxylase (AADC), the three enzymes
needed for dopamine synthesis from L-tyrosine (Azzouz et al.,
2002). However, continuous neurodegeneration remains a major
issue over time. The loss of neurons in the substantia nigra
and other brain regions decreases the efficacy of dopamine
replacement therapies and ultimately leads to the emergence of
non-motor symptoms such as sleep disorders, as well as mood
and cognitive dysfunctions. Based on the genetic causes of PD, or
risk factors involved in disease etiology, novel approaches have
been proposed to protect neurons and slow down the course of
the disease (summarized in Figure 1). Although causal genetic
mutations account for only 10% of the patients, the familial
forms of the disease could represent a first rational target for
gene therapy. Furthermore, neuroprotective factors that are
not directly involved in the pathogenesis, such as neurotrophic
factors, have also been considered. Based on these examples, we
discuss the use of gene delivery as a neuroprotective approach in
PD.
WHY CONSIDERING GENE THERAPY FOR
NEUROPROTECTION AGAINST
PARKINSON’S DISEASE?
Historically, PD has been a major focus for gene therapy in
the CNS. The use of gene delivery as a potential treatment has
been mainly driven by the possibility to target the nigrostriatal
system, which degenerates in PD and is responsible for the main
motor symptoms. The substantia nigra contains a population
of less than 500,000 dopaminergic neurons per hemisphere in
humans, and their cell soma are distributed within a small
volume of the ventral midbrain (Rudow et al., 2008). Nigral
dopamine neurons develop an extensive axonal arborization in
the striatum, a key structure in the basal ganglia. It is feasible to
locally inject viral vectors to genetically modify these neurons,
or glial cells localized in their direct environment. Both Adeno-
associated virus (AAV) and lentiviral vectors have proved highly
effective to deliver genes either in the substantia nigra or in the
striatum (Lundberg et al., 2008; Löw et al., 2013). Therefore,
the administration of neuroprotective genes has appeared as a
realistic therapeutic option. At the same time, the development
of symptomatic treatments to restore the proper function of the
basal ganglia, such as chronic levodopa administration and deep
brain stimulation, has made constant progress. The significant
effects of these treatments on themotor symptoms of PD raise the
bar for gene therapy. Indeed, the risk-to-benefit balance has to be
carefully addressed for treatments that are based on permanent
gene delivery, a technology which is still considered risky for
conditions that are not life-threatening. However, as none of the
existing treatments can prevent PD progression, there is still a
major unmet therapeutic need.
The past two decades have witnessed major developments
in our understanding of PD etiology. In particular, a number
of genes have been found to have a causal role in familial
forms of PD, including α-synuclein, Leucine-rich repeat kinase 2
(LRRK2), parkin and PTEN-induced putative kinase 1 (PINK1)
(for review see Hernandez et al., 2016). Other genes, such as
β-glucocerebrosidase (GBA1), are considered as risk factors for
the disease and may also offer opportunities for gene therapy.
Altogether, although PD does not appear to be linked to a single
pathway, these genetic factors point to changes in mitochondrial
and lysosomal activities as a key axis in the pathogenesis.
However, uncertainty prevails regarding how to address these
pathogenic mechanisms using gene therapy.
What Are the Genetic Causes of
Parkinson’s Disease That Can Be Targeted
by Gene Therapy?
The overabundance of α-synuclein, a small presynaptic protein,
is considered a major pathogenic mechanism in both genetic
and sporadic forms of PD. The rare familial forms linked
to mutations and multiplications of the α-synuclein gene, as
well as the finding that α-synuclein is the main constituent of
Lewy bodies, support this notion. Overall, conditions leading
to the misfolding of this protein may contribute to the
disease. The level of α-synuclein is therefore considered to
be a critical factor. Gene therapy has been proposed for
RNA interference against α-synuclein, assuming it would be
possible to substantially decrease the level of the protein
without inducing major side effects (Khodr et al., 2011,
2014). However, silencing of α-synuclein has led to nigral
degeneration in rats and primates, a robust effect which is at
odds with the minor phenotypes observed in α-synuclein-null
mouse strains (Gorbatyuk et al., 2010; Collier et al., 2016).
Furthermore, α-synuclein has been found implicated in vesicular
neurotransmitter release (Burré, 2015), suggesting that the level
of α-synuclein may have to be carefully adjusted to avoid
defects in neurotransmission. Overall, controlling α-synuclein
levels in neurons by gene therapy appears as a challenging task,
which will require a better understanding of the mechanisms
that control the homeostasis of this protein in health and
disease.
Genes involved in recessive forms of familial PD may
represent easier targets for gene therapy, with the aim to
rescue proper gene function. In particular, loss-of-function
mutations in the genes encoding Parkin and PINK1 are together
responsible for a significant number of recessive PD cases.
These two genes are active in the same pathway (Clark et al.,
2006; Park et al., 2006). Although the overall role of this
pathway in selectively vulnerable populations of neurons remains
unclear, there is increasing evidence for its involvement in
the control of mitochondrial turnover, by inducing mitophagy
via the ubiquitination of mitochondrial proteins (Narendra
et al., 2008). As loss-of-function mutations can be potentially
rescued by overexpressing the functional protein, this may
represent a possible candidate application for gene therapy in
PD. However, patients who carry Parkin mutations have an
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FIGURE 1 | Proposed gene therapies for neuroprotection against Parkinson’s disease (PD). Based on the identified causes and risk factors for PD, various
strategies have been envisaged, including RNA interference against α-synuclein and Parkin overexpression. Gene transfer has been proposed to deliver neurotrophic
factors to rescue dopaminergic function, factors to suppress endoplasmic reticulum (ER) stress, enhance lysosomal and mitochondrial activities.
atypical form of Parkinsonism characterized by early onset
and slow disease progression (Lohmann et al., 2003). Lewy
bodies positively stained for α-synuclein are in most cases
not observed in the substantia nigra (Mori et al., 1998). In
these patients, the motor symptoms can be efficiently corrected
by levodopa administration. The efficacy of the symptomatic
treatments opposes the use of gene therapy for the rescue of
Parkin activity as a possible alternative treatment. Furthermore,
it remains unclear if chronically enhancing the activity of the
PINK1-Parkin pathway may represent a therapeutic option for
sporadic PD cases, as suggested by the neuprotective effects
of Parkin overexpression on neurons exposed to α-synuclein
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toxicity (Lo Bianco et al., 2004b; Yasuda et al., 2007). Indeed,
the long-term chronic overexpression of Parkin may even
cause adverse effects such as the loss of neurons positive
for dopaminergic markers in the nigrostriatal system, which
raises the need for careful vector dosing (Van Rompuy et al.,
2014).
Although the therapeutic use of gene delivery appears
challenging in the context of PD, the expanding list of
genes implicated in PD may reveal novel options for gene
therapy. In addition, the use of novel targeted gene editing
technologies, such as the bacterial Clustered regularly
interspaced short palindromic repeats (CRISPR)-associated
protein-9 nuclease (Cas9), provides novel modalities for more
precise intervention on the genetic defects that underlie the
disease. It is therefore plausible that gene therapy may ultimately
find application for neuroprotection in the familial forms of the
disease.
IDENTIFYING KEY DOWNSTREAM
TARGETS
Autophagy
Although pathogenic pathways implicated in PD are intensively
investigated, the possible mechanisms that may represent
common denominators between genetic and idiopathic PD have
remained rather elusive. Nevertheless, some risk factors have
been identified that appear to be critical mediators of the
lysosomal and mitochondrial activities. The GBA1 gene encodes
the lysosomal enzyme β-glucocerebrosidase (GCase), which is
involved in the conversion of glucosylceramide into glucose and
ceramide. Whereas the complete loss of GCase activity leads
to Gaucher disease, heterozygous carriers of GBA1 mutations
have increased risk of developing PD (Neumann et al., 2009).
During aging and in PD, a progressive decrease of GCase activity
is observed (Rocha et al., 2015a). Furthermore, reduced GCase
activity leads to enhanced levels of α-synuclein, which in turn
further affect GCase (Mazzulli et al., 2011). This vicious circle
leads to impaired lysosomal function. A possible therapeutic
approach is to rescue GCase activity (Mazzulli et al., 2016).
As it is difficult to administer the recombinant enzyme to
the CNS, an alternative approach is to deliver GBA1 by gene
therapy. In the rat substantia nigra overexpressing human A53T
α-synuclein, co-injection of an AAV vector encoding GCase has
neuroprotective effects on dopaminergic neurons (Rocha et al.,
2015b). Furthermore, the same vector injected in transgenic mice
overexpressing wild-type human α-synuclein led to a reduction
of the high molecular weight α-synuclein species, and decreased
the insoluble α-synuclein aggregates in the substantia nigra and
striatum.
Alternatively, it is also possible to enhance autophagy by
overexpressing critical factors controlling lysosomal activity.
In particular, the transcription factor TFEB, which regulates
genes involved in the ‘‘Coordinated Lysosomal Expression and
Regulation’’ (CLEAR) network, has been found clustered in
the cytosol of diseased dopaminergic neurons (Decressac and
Björklund, 2013). Markers of autophagic activity were found
to be dysregulated in neurons overexpressing α-synuclein.
Based on these observations, Decressac et al. (2013) found
that AAV-mediated expression of either TFEB or Beclin-1,
another key regulator of the autophagy-lysosome pathway,
had clear neuroprotective effects on rat nigral dopaminergic
neurons overexpressing human α-synuclein. Notably, the
injection of these viral vectors induced local protection of
both neuronal cell bodies and their striatal projections, and
improved dopamine neurotransmission. Considering that the
activities of GCase and transcription factor EB (TFEB) could
be interdependent (Sardiello et al., 2009; Awad et al., 2015),
these studies highlight the possibility of locally enhancing
the autophagy-lysosome activity by gene therapy, to provide
neuroprotective effects against the accumulation of α-synuclein.
Furthermore, restoring lysosomal activity may also reduce
intercellular transmission of the α-synuclein pathology,
which may affect disease progression (Kim et al., 2016).
However, before envisaging gene therapy to increase autophagy-
lysosome activity, it will be critical to explore the long-term
effects, as deregulated autophagy can lead to neuronal cell
death.
Mitochondrial Activity
PD has been notoriously associated with defects in the
mitochondrial function. A notion further supported by the
effects of mitochondrial toxins, such as rotenone and 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which lead
to syndromes characterized by the selective degeneration
of dopaminergic neurons in the substantia nigra. More
recently, factors implicated in familial forms of PD, such
as Parkin/PINK1 and α-synuclein, have also been found to
directly affect mitochondria. In line with the primary role of
mitochondria in PD, a meta-analysis of gene expression changes
found in the substantia nigra identified a set of genes implicated
in bioenergetics to be consistently downregulated in PD (Zheng
et al., 2010). In particular, several of these genes share Peroxisome
proliferator-activated receptor gamma coactivator 1-alpha
(PGC-1α), a master regulator of mitochondrial biogenesis,
as a common factor regulating their transcription. Therefore,
PGC-1α has been proposed as a therapeutic target in PD, which
is further supported by the direct interaction between PGC-1α
activity and the α-synuclein pathology and by the finding
that Parkin controls PGC-1α expression via the proteasomal
degradation of PARIS, a transcriptional repressor of PGC-1α
(Shin et al., 2011). AAV-mediated gene therapy to provide
neuroprotection by increasing PGC-1α expression has been
addressed in rodent models of PD. The neuroprotective
effects were tested in neurons either overexpressing human
α-synuclein, or exposed to the MPTP neurotoxin (St-Pierre
et al., 2006). Although significant protection was achieved in
acute models of neurotoxicity, these experiments also revealed
a clear down-regulation of dopaminergic markers following
chronic expression of PGC-1α at supraphysiologic levels (Ciron
et al., 2012). This effect was linked to a down-regulation of Pitx3,
a factor controlling the expression of important genes in the
differentiation of dopamine neurons (Clark et al., 2012). When
PGC-1αwas expressed at high levels for several months in the rat
substantia nigra, selective degeneration of nigral dopaminergic
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occurred, possibly caused by the accumulation of defective
mitochondria (Ciron et al., 2012). Remarkably, PGC-1α null
mice are more susceptible to PD-related stress, in particular to
the toxic effects of human α-synuclein overexpression (Ciron
et al., 2015). In this context, which perhaps mimics more closely
the pathologic conditions of PD, AAV-mediated expression
of PGC-1α had protective effects against α-synuclein-induced
neurodegeneration (Ciron et al., 2015). These results underline
the need to maintain the level of PGC-1α activity within a
therapeutic window, which may be difficult to achieve over the
long term via gene therapy.
ER Stress
Among the pathogenic mechanisms that affect neurons in PD,
stress of the endoplasmic reticulum (ER) and the subsequent
unfolded protein response (UPR) may play an important role.
ER stress is broadly observed in several models of the disease
(Mercado et al., 2013), and markers of ER stress and activation
of the UPR have also been detected in post-mortem tissue and
iPSC-derived neurons obtained from PD patients (Chung et al.,
2013). ER stress is therefore emerging as a potential pathogenic
mechanism, which raises the possibility of targeting the UPR
as a potential therapeutic approach. In mammals, upon stress
caused by the presence of misfolded proteins in the ER lumen,
the UPR is triggered by the activation of three transmembrane
sensor proteins: IRE1α, ATF6 and PERK. Once activated, these
sensor proteins induce the activation of three transcription
factors, XBP1s, ATF6f and ATF4, which translocate to the
nucleus to regulate the expression of genes involved in protein
folding and quality control, protein secretion, autophagy, protein
degradation and ultimately apoptosis (Walter and Ron, 2011).
Under acute ER stress conditions, the UPR mediates cellular
adaptation to restore ER homeostasis. However, when the stress
becomes chronic, the same pathway can trigger apoptosis to
eliminate the damaged cells.
Several approaches have been considered to decrease the
levels of ER stress and control the UPR by gene therapy. One
strategy could be to directly target the accumulation of misfolded
proteins in the lumen of the ER of dopaminergic neurons to
avoid the activation of pathogenic downstream mechanisms.
Accumulation of α-synuclein in experimental rodent models
leads to ER stress and activation of the UPR. In this context,
Gorbatyuk et al. (2012) delivered an AAV vector into the SNpc to
induce overexpression of GRP78/BiP, an ER-resident chaperone
modulating ER stress. GRP78/BiP was found to promote the
survival of nigral dopaminergic neurons in rats overexpressing
α-synuclein, with a decrease of ER stress and apoptotic markers
(Salganik et al., 2015). Gene therapy was able to protect neurons,
rescue dopamine levels in the striatum, and significantly correct
the motor impairments observed in this animal model.
Alternatively, it is also possible to selectively modulate one
arm of the UPR by gene therapy. Target selection in this
complex pathway is not a simple task, and the effects of the
factors critically involved in UPR are poorly predictable. Silva
and collaborators showed that in mice deficient for C/EBP
homologous protein (CHOP), a transcription factor implicated
in apoptosis caused by ER stress and activated by the PERK
pathway, dopaminergic neurons are protected against MPTP
(Silva et al., 2005). However, as this work was based on CHOP
null mice, it is also possible that compensatory mechanisms
have contributed to the observed neuroprotection. Although
gene therapy approaches to block CHOP activity have not
been tested yet, one study was based on the AAV-mediated
overexpression of ATF4, a transcription factor activated by PERK
and upstream of CHOP (Gully et al., 2016). ATF4 expression
induced the loss of dopaminergic nigral neurons in a rat
model of PD, suggesting that this arm of the UPR pathway
could indeed play a critical role in the degeneration of these
neurons.
Decreasing the overload of misfolded proteins at the ER
could also be achieved through the activation of the IRE1α
pathway. Two studies attempted to genetically manipulate
this UPR arm as a potential therapy for PD. XBP-1s is a
transcription factor activated by IRE1α and that controls a subset
of genes involved in protein folding, ER/Golgi biogenesis and
ER-associated degradation of proteins. The delivery of an AAV
vector encoding XBP-1s into the substantia nigra increases the
survival of dopaminergic neurons in two different neurotoxin-
based models of the disease (Sado et al., 2009; Valdés et al.,
2014). Although the exact protective mechanism remains elusive,
it is likely that the activation of this UPR pathway can alleviate
the ER stress triggered by the neurotoxins. Moreover, as the
silencing of XBP-1s in adult mice was shown to rapidly trigger the
death of nigral dopaminergic neurons, this factor seems to play
a critical role in the maintenance and survival of these neurons
even in physiological conditions (Valdés et al., 2014). Gene
therapy based on the delivery of XBP-1s is a promising approach
for PD. However, the multifaceted roles of this factor have
to be carefully considered before envisaging chronic activation
of this pathway. Notably, a recent study has shown a role of
XBP-1s in memory formation, indicating that potent effects are
to be expected in various neuronal systems (Martínez et al.,
2016).
NEUROPROTECTION WITH GENES
ENCODING NEUROTROPHIC FACTORS
Gene delivery has been used to express neurotrophins, as
these proteins typically poorly penetrate the brain parenchyma.
The delivery of neurotrophic factors by gene therapy has
proved very effective for neurorestoration of dopaminergic
neurons in the context of PD. Local delivery of neurotrophins,
such as glial cell derived neurotrophic factor (GDNF) and
neurturin, leads to enhanced dopamine synthesis, axonal
sprouting and the generation of novel synaptic connections,
which translates into improved motor function. The restorative
effect of neurotrophins is particularly evident following acute
and selective lesions of the nigrostriatal dopaminergic system
with selective toxicants, such as 6-hydroxydopamine (6-OHDA)
and MPTP (Kordower et al., 2000). However, it remains unclear
whether neurotrophic factors can provide effective protection in
PD. Notably, the effects of GDNF was found to be dramatically
reduced in presence of the α-synuclein pathology (Lo Bianco
et al., 2004a; Decressac et al., 2011). Impaired GDNF signaling
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is caused by the decreased expression of the transcription
factor Nurr1 in dopaminergic neurons overexpressing human
α-synuclein, which leads to lower expression of the GDNF
receptor Ret (Decressac et al., 2012). A gene therapy approach
combining Nurr1 and Foxa2 has recently been tested in
MPTP-treated mice (Oh et al., 2015). Neuroprotective effects
were obtained, lasting for up to 1 year after AAV vector injection.
However, the efficacy of this approach remains to be tested in
genetic models of PD.
AAV-based gene therapy has been used in PD patients to
deliver neurturin, a neurotrophic factor which is part of the
GDNF family, with a similar mode of action. AAV2-neurturin
(CERE-120) was tested in one open-label phase I trial followed
by a phase II trial, using bilateral intraputaminal delivery of
the vector in moderately advanced PD patients (Marks et al.,
2008, 2010). The results did not demonstrate any significant
benefit in the UPDRS score compared to the sham-operated
group. As there was little expression of neurturin in the
substantia nigra, a follow-up trial assessed patients injected
with the vector in both the putamen and the substantia nigra
(Warren Olanow et al., 2015). However, there was no significant
effect of AAV2-neurturin compared to sham surgery. A trial is
currently ongoing to test the effect of a similar AAV2-GDNF
vector.
Overall, it remains unclear whether the delivery of
neurotrophic factors by gene therapy has the potential to
slow down disease progression in PD. The results of the initial
trials have been disappointing, and it is unclear if neurotrophic
factors of the GDNF family can exert protective effects in
the context of the α-synuclein pathology. However, novel
neurotrophins with different modes of actions have been found,
such as mesencephalic astrocyte derived neurotrophic factor
(MANF) and cerebral dopamine neurotrophic factor (CDNF;
Petrova et al., 2003; Lindholm et al., 2007). These factors have
potent trophic effects on dopaminergic neurons. In addition,
they reside in the ER, where they interact with GRP78/BiP and
control ER stress (Lindahl et al., 2016). It will be critical to
determine the effects of these factors in the context of the PD
pathology, and if they can be safely delivered by gene therapy
(Bäck et al., 2013).
CONCLUSIONS
The use of gene therapy for neuroprotection in PD has
to be continuously reassessed in the light of the recent
findings regarding disease etiology. While genes implicated
in the familial forms of the disease represent the most
rational targets for gene therapy, it has been difficult to
establish proof-of-concept for rescue approaches. The disease
appears to perturb lysosomal and mitochondrial activities
that are essential to the long-term maintenance of neuronal
homeostasis. Neuroprotective approaches to support these
pathways often cause unexpected effects, in particular when
genetic modifications lead to long-lasting changes in the
expression of key factors. In addition, it is now considered that
misfolded and aggregated α-synuclein deposits that represent
a hallmark of PD pathology, may propagate through neuronal
systems in the peripheral and CNS, via mechanisms that remain
unclear. The pathology appears no more restricted to the
nigrostriatal system, and the motor symptoms linked to the
selective vulnerability of the dopamine neurons, and which have
been the main target for gene therapy so far, are likely to be
the tip of the iceberg. Hence, PD should be considered as a
complex syndrome that will likely require combined therapeutic
interventions for effective treatment. Novel gene delivery tools
show unprecedented efficacy in the CNS, and more precise
techniques are currently being developed for genetic correction.
By supporting the survival of neurons that are chronically
exposed to the disease, it is likely that gene therapy will become
part of the arsenal needed for neuroprotection.
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